Improving Severe Combined Immunodeficiency and Cystic Fibrosis Newborn Screening by Replacing Current Tests with First-Tier Targeted Gene Sequencing
International Journal of Neonatal Screening · 23.07.2026 · 12 (3) · 56
DOI: 10.3390/ijns12030056 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Neonatal Screening, online erschienen am 23.07.2026. Verfasst von Bennett O V Shum und 6 weiteren Autor:innen. Beteiligte Einrichtung: Preventive Health Division, Genepath, Sydney, NSW 2067, Australia. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Genepath, Pathology Queensland.
Abstract (Originalsprache)
Newborn screening benefits children with rare diseases by enabling early detection and intervention, which improves health outcomes. False-positive results are one harm of screening, with infants subject to further testing to resolve a positive screen and parents susceptible to psychosocial distress while awaiting the results. Newborn bloodspot screening (NBS) for severe combined immunodeficiency (SCID) using quantitative polymerase chain reaction (qPCR) and cystic fibrosis (CF) screening using immunoreactive trypsinogen (IRT) have high false-positive rates, with more than five infants screening positive and unaffected, for each child diagnosed. We used first-tier targeted gene sequencing (TGS) to prospectively screen 3025 newborns for CF, SCID and spinal muscular atrophy (SMA) and compared the results to current screening protocols using multiplex qPCR and IRT. TGS identified one infant with CF, missed by the IRT assay, and detected an infant with SMA, who screened positive with multiplex qPCR. TGS had zero false-positive results for SCID, CF and SMA. By contrast, multiplex qPCR and IRT screening protocols had approximately nine false positives for each child diagnosed with CF (positive predictive value, PPV 10.00%) and SCID (PPV 10.13%). Replacing current SCID and CF screening protocols with TGS would reduce NBS false positives and may result in a higher sensitivity for CF. TGS sensitivity and specificity would be comparable to qPCR for SMA. A larger trial is required to determine TGS sensitivity and cost-effectiveness.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Preventive Health Division, Genepath, Sydney, NSW 2067, Australia.
- EMBL Australia Node in Single Molecule Science, School of Biomedical Sciences, University of NSW, Sydney, NSW 2052, Australia.
- Department of Chemical Pathology, Pathology Queensland, Queensland Health, Brisbane, QLD 4029, Australia.
- Faculty of Health and Behavioural Sciences, University of QLD, Brisbane, QLD 4072, Australia.
ORCID-Profile: Bennett O V Shum, Carel Pretorius, Urs Wilgen, Glenn Bennett, Jacobus P J Ungerer
Förderung
- Genepath
- Pathology Queensland
Zitieren
APA
Shum, B. O. V., Pretorius, C., Henner, I., Basar, E., Wilgen, U., Bennett, G., & Ungerer, J. P. J. (2026). Improving Severe Combined Immunodeficiency and Cystic Fibrosis Newborn Screening by Replacing Current Tests with First-Tier Targeted Gene Sequencing. International Journal of Neonatal Screening, 12(3), 56. https://doi.org/10.3390/ijns12030056
Vancouver
Shum BOV, Pretorius C, Henner I, Basar E, Wilgen U, Bennett G, et al. Improving Severe Combined Immunodeficiency and Cystic Fibrosis Newborn Screening by Replacing Current Tests with First-Tier Targeted Gene Sequencing. International Journal of Neonatal Screening. 2026;12(3):56. doi:10.3390/ijns12030056
BibTeX
@article{Shum2026,
author = {Shum, Bennett O V and Pretorius, Carel and Henner, Ilya and Basar, Emre and Wilgen, Urs and Bennett, Glenn and Ungerer, Jacobus P J},
title = {Improving Severe Combined Immunodeficiency and Cystic Fibrosis Newborn Screening by Replacing Current Tests with First-Tier Targeted Gene Sequencing},
journal = {International Journal of Neonatal Screening},
year = {2026},
volume = {12},
number = {3},
pages = {56},
doi = {10.3390/ijns12030056}
}
EUVIMED